Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789920 | PMC |
| http://dx.doi.org/10.1038/s41408-022-00612-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding Brain Development and Aging: Pioneering Insights From MRI Techniques.
Invest Radiol
October 2024
From the Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan (A.H., S.K., J.K., M.N., W.U., S.F., T.A., A.W., K.K., S.A.); Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (A.H., M.N., S.F.); Polytechnique Montréal, Montreal, Quebec, Canada (S.N.); Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada (S.N.); and Center for Advanced Interdisciplinary Research, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia (S.N.).
The aging process induces a variety of changes in the brain detectable by magnetic resonance imaging (MRI). These changes include alterations in brain volume, fluid-attenuated inversion recovery (FLAIR) white matter hyperintense lesions, and variations in tissue properties such as relaxivity, myelin, iron content, neurite density, and other microstructures. Each MRI technique offers unique insights into the structural and compositional changes occurring in the brain due to normal aging or neurodegenerative diseases.
View Article and Find Full Text PDFCurrent opinions: updates on the changing landscape in the management of cervical cancer.
Curr Opin Obstet Gynecol
September 2024
Jonsson Comprehensive Cancer Center, University of California.
Purpose Of Review: To review the recent updates in the management of cervical cancer across all stages of the disease.
Recent Findings: After decades of minor advances, the landscape in cervical cancer is now rapidly changing. Recent studies have reported across the cervical cancer spectrum and on different therapeutic modalities.
Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term.
Neurology
January 2025
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Background And Objectives: Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ/Aβ ratio), tau (p-tau), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI.
View Article and Find Full Text PDFDeveloping a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.
FASEB J
December 2024
Antibody and Vaccine Group, Faculty of Medicine, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Southampton, UK.
Osteosarcoma is the most common primary bone cancer, occurring frequently in children and young adults. Patients are treated with surgery and multi-agent chemotherapy, and despite the introduction of mifamurtide in 2011, there has been little improvement in survival for decades. 3-dimensional models offer the potential to understand the complexity of the osteosarcoma tumor microenvironment and aid in developing new treatment approaches.
View Article and Find Full Text PDFSARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study.
Infect Dis Ther
December 2024
Roche Diagnostics GmbH, Nonnenwald 2, 81377, Penzberg, Germany.
Introduction: The use of antibody titers against SARS-CoV-2, as a method of estimating subsequent infection following infection or vaccination, is unclear. Here, we investigate whether specific levels of antibodies, as markers of adaptive immunity, can serve to estimate the risk of symptomatic SARS-CoV-2 (re-) infection.
Methods: In this real-world study, laboratory data from individuals tested for SARS-CoV-2 antibodies under routine clinical conditions were linked through tokenization to a United States medical insurance claims database to determine the risk of symptomatic/severe SARS-CoV-2 infection outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!